What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Jared Whitlock

Features Editor

President-elect Donald Trump’s two picks for the Federal Trade Commission are likely to usher in more life sciences deals while maintaining the agency’s pressure on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Jared Whitlock

Features Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Features Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

What Trump’s FTC picks mean for biopharma dealmaking and PBMs